|
1
|
Parascandola M and Xiao L: Tobacco and the
lung cancer epidemic in China. Transl Lung Cancer Res. 8
(Suppl):S21–S30. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W: Cancer statistics: Updated cancer
burden in China. Chin J Cancer Res. 27:12015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oser MG, Niederst MJ, Sequist LV and
Engelman JA: Transformation from non-small-cell lung cancer to
small-cell lung cancer: Molecular drivers and cells of origin.
Lancet Oncol. 16:e165–e172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thatcher N, Faivre-Finn C, Blackhall F,
Anderson H and Lorigan P: Sequential platinum-based
chemotherapy-thoracic radiotherapy in early stage non-small cell
lung cancer. Clin Cancer Res. 11 (Suppl):S5051–S5056. 2005.
View Article : Google Scholar
|
|
5
|
Yano T, Okamoto T, Fukuyama S and Maehara
Y: Therapeutic strategy for postoperative recurrence in patients
with non-small cell lung cancer. World J Clin Oncol. 5:1048–1054.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fang Z, Chen W, Yuan Z, Liu X and Jiang H:
LncRNA-MALAT1 contributes to the cisplatin-resistance of lung
cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed
Pharmacother. 101:536–542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cai Y, Dong ZY and Wang JY: LncRNA NNT-AS1
is a major mediator of cisplatin chemoresistance in non-small cell
lung cancer through MAPK/Slug pathway. Eur Rev Med Pharmacol Sci.
22:4879–4887. 2018.PubMed/NCBI
|
|
8
|
Han ML, Zhao YF, Tan CH, Xiong YJ, Wang
WJ, Wu F, Fei Y, Wang L and Liang ZQ: Cathepsin L
upregulation-induced EMT phenotype is associated with the
acquisition of cisplatin or paclitaxel resistance in A549 cells.
Acta Pharmacol Sin. 37:1606–1622. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu J, Meisner D, Kwong E, Wu XY and
Johnston MR: Translymphatic chemotherapy by intrapleural placement
of gelatin sponge containing biodegradable Paclitaxel colloids
controls lymphatic metastasis in lung cancer. Cancer Res.
69:1174–1181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hassan WA, Yoshida R, Kudoh S, Kameyama H,
Hasegawa K, Niimori-Kita K and Ito T: Notch1 controls cell
chemoresistance in small cell lung carcinoma cells. Thorac Cancer.
7:123–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang H, Jiang L, Zhu C, Liu R, Wu Y, Yan
Q, Liu M, Jia Y, Chen J, Qin Y, et al: Loss of cell adhesion
molecule L1 like promotes tumor growth and metastasis in esophageal
squamous cell carcinoma. Oncogene. 38:3119–3133. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu H, Focia PJ and He X: Homophilic
adhesion mechanism of neurofascin, a member of the L1 family of
neural cell adhesion molecules. J Biol Chem. 286:797–805. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tassano E, Biancheri R, Denegri L, Porta
S, Novara F, Zuffardi O, Gimelli G and Cuoco C: Heterozygous
deletion of CHL1 gene: Detailed array-CGH and clinical
characterization of a new case and review of the literature. Eur J
Med Genet. 57:626–629. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morellini F, Lepsveridze E, Kahler B,
Dityatev A and Schachner M: Reduced reactivity to novelty, impaired
social behavior, and enhanced basal synaptic excitatory activity in
perforant path projections to the dentate gyrus in young adult mice
deficient in the neural cell adhesion molecule CHL1. Mol Cell
Neurosci. 34:121–136. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He LH, Ma Q, Shi YH, Ge J, Zhao HM, Li SF
and Tong ZS: CHL1 is involved in human breast tumorigenesis and
progression. Biochem Biophys Res Commun. 438:433–438. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martín-Sánchez E, Mendaza S,
Ulazia-Garmendia A, Monreal-Santesteban I, Blanco-Luquin I, Córdoba
A, Vicente-García F, Pérez-Janices N, Escors D, Megías D, et al:
CHL1 hypermethylation as a potential biomarker of poor prognosis in
breast cancer. Oncotarget. 8:15789–15801. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu H, Fang J, Zhang J, Zhao Z, Liu L,
Wang J, Xi Q and Gu M: miR-182 targets CHL1 and controls tumor
growth and invasion in papillary thyroid carcinoma. Biochem Biophys
Res Commun. 450:857–862. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu W, Zhu K, Wang Y, Yu H and Guo J:
Overexpression of miR-21-5p promotes proliferation and invasion of
colon adenocarcinoma cells through targeting CHL1. Mol Med.
24:362018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hötzel J, Melling N, Müller J, Polonski A,
Wolters-Eisfeld G, Izbicki JR, Karstens KF and Tachezy M: Protein
expression of close homologue of L1 (CHL1) is a marker for overall
survival in non-small cell lung cancer (NSCLC). J Cancer Res Clin
Oncol. 145:2285–2292. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun Y, Zheng S, Torossian A, Speirs CK,
Schleicher S, Giacalone NJ, Carbone DP, Zhao Z and Lu B: Role of
insulin-like growth factor-1 signaling pathway in
cisplatin-resistant lung cancer cells. Int J Radiat Oncol Biol
Phys. 82:e563–e572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41((Database issue)):
D991–D995. 2013.PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Y, Wang H, Xiong T, Zou R, Tang Z and
Wang J: The role of LASS2 in regulating bladder cancer cell
tumorigenicity in a nude mouse model. Oncol Lett. 14:5149–5156.
2017.PubMed/NCBI
|
|
24
|
Ognibene M, Pagnan G, Marimpietri D,
Cangelosi D, Cilli M, Benedetti MC, Boldrini R, Garaventa A,
Frassoni F, Eva A, et al: CHL1 gene acts as a tumor suppressor in
human neuroblastoma. Oncotarget. 9:25903–25921. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Senchenko VN, Krasnov GS, Dmitriev AA,
Kudryavtseva AV, Anedchenko EA, Braga EA, Pronina IV, Kondratieva
TT, Ivanov SV, Zabarovsky ER and Lerman MI: Differential expression
of CHL1 gene during development of major human cancers. PLoS One.
6:e156122011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chu Y, Ouyang Y, Wang F, Zheng A, Bai L,
Han L, Chen Y and Wang H: MicroRNA-590 promotes cervical cancer
cell growth and invasion by targeting CHL1. J Cell Biochem.
115:847–853. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Long MJ, Wu FX, Li P, Liu M, Li X and Tang
H: MicroRNA-10a targets CHL1 and promotes cell growth, migration
and invasion in human cervical cancer cells. Cancer Lett.
324:186–196. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang Z, Xie Q, Hu CL, Jiang Q, Shen HF,
Schachner M and Zhao WJ: CHL1 is expressed and functions as a
malignancy promoter in glioma cells. Front Mol Neurosci.
10:3242017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi CH, Choi JJ, Park YA, Lee YY, Song
SY, Sung CO, Song T, Kim MK, Kim TJ, Lee JW, et al: Identification
of differentially expressed genes according to chemosensitivity in
advanced ovarian serous adenocarcinomas: Expression of GRIA2
predicts better survival. Br J Cancer. 107:91–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baharudin R, Ab Mutalib NS, Othman SN,
Sagap I, Rose IM, Mohd Mokhtar N and Jamal R: Identification of
predictive DNA methylation biomarkers for chemotherapy response in
colorectal cancer. Front Pharmacol. 8:472017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang CK, Zhang Y, Zhang ZJ, Qiu QW, Cao JG
and He ZM: Effects of VBMDMP on the reversal of cisplatin
resistance in human lung cancer A549/DDP cells. Oncol Rep.
33:372–382. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao Y, Wang Y, Li Y, Han R, Li C, Xiao L,
Cho S, Ma Y, Fang C and Lee AW: Repeated sub-chronic oral toxicity
study of xylooligosaccharides (XOS) in dogs. Regul Toxicol
Pharmacol. 86:379–385. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu YH, Huang YF, Chen CC and Chou CY: Akt
inhibitor SC66 promotes cell sensitivity to cisplatin in
chemoresistant ovarian cancer cells through inhibition of COL11A1
expression. Cell Death Dis. 10:3222019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Clark AS, West K, Streicher S and Dennis
PA: Constitutive and inducible Akt activity promotes resistance to
chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol
Cancer Ther. 1:707–717. 2002.PubMed/NCBI
|
|
35
|
Imai Y, Yamagishi H, Ono Y and Ueda Y:
Versatile inhibitory effects of the flavonoid-derived PI3K/Akt
inhibitor, LY294002, on ATP-binding cassette transporters that
characterize stem cells. Clin Transl Med. 1:242012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sims JT, Ganguly SS, Bennett H, Friend JW,
Tepe J and Plattner R: Imatinib reverses doxorubicin resistance by
affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT
pathways and by inhibiting ABCB1. PLoS One. 8:e555092013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang X, He S, Gu Y, Wang Q, Chu X, Jin M,
Xu L, Wu Q, Zhou Q, Wang B, et al: Fatty acid receptor GPR120
promotes breast cancer chemoresistance by upregulating ABC
transporters expression and fatty acid synthesis. EBioMedicine.
40:251–262. 2019. View Article : Google Scholar : PubMed/NCBI
|
